A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration
Latest Information Update: 23 May 2024
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Sponsors CURATEQ BIOLOGICS PRIVATE LIMITED
Most Recent Events
- 23 May 2024 Last checked against European Union Clinical Trials Register record.
- 01 Apr 2024 New trial record